Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today ...

Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for AML and Multiple Myeloma IND Cleared for FT819, the First iPSC-derived CAR T-cell Therapy, for Advanced B-cell Leukemias ...

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...

One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...